Resurrect Bio Secures €8.8 Million Funding to Pioneer Disease-Resistant Crop Innovation in UK AgriBioTech Sector

Resurrect Bio Secures €8.8 Million in Series A Funding Round

Resurrect Bio, a pioneering agricultural BioTech startup based in London, has successfully concluded its oversubscribed Series A funding round, raising a total of €8.8 million ($10.3 million). This achievement follows an initial close of over €6.8 million ($8 million) in February 2026 as part of the Series A round.

The funding round was spearheaded by Corteva through its Corteva Catalyst platform, with significant contributions from Calculus Capital, Pymwymic, UKI2S (managed by Future Planet Capital), SynBioVen, and AgFunder. With this final closing, Resurrect Bio has amassed approximately $12.4 million in total funding since its inception, inclusive of the Seed round in 2023.

Dr. Cian Duggan, the CEO of Resurrect Bio, expressed his enthusiasm about the successful fundraising, stating, “The strength of this raise reflects growing conviction in what we’re building: a scalable, AI-driven platform for resurrecting disease resistance in the world’s most crucial crops. It’s also a validation of the potential when combining the UK’s exceptional plant science expertise with commercial ambition to drive real-world impact.”

He further added, “We’re expanding our team, enhancing our platforms, and actively pursuing joint development agreements with seed companies and breeders interested in introducing durable resistance traits to farmers.”

Founded in 2022 by Prof. Sophien Kamoun, Prof. Tolga Bozkurt, and Dr. Cian Duggan, Resurrect Bio originated from The Sainsbury Laboratory in Norwich. The company’s primary objective is to emerge as a global leader in plant disease resistance, crafting both in-house traits and collaborating with premier seed companies to safeguard crops.

Resurrect Bio offers the seed industry an eco-friendly alternative to chemical crop protection by reinvigorating complex resistance mechanisms. The company’s fundamental technology revolves around the concept that pathogens evolve to debilitate the crop’s immune response, leading to disease. By resurrecting the immune system, Resurrect Bio effectively blocks pathogens from infiltrating the crop.

The newly acquired funds will be channeled towards expanding Resurrect Bio’s three core competencies: the FloraFold® AI in silico discovery platform, which anticipates interactions between plant and pathogen proteins; the high-throughput functional biology platform, which validates these predictions on a large scale; and the Resurrection platform, which reactivates latent resistance mechanisms inherent in elite germplasm.

These platforms collectively streamline the timeline from discovery to implementation in crop production, significantly expediting the process.

Elizabeth Klein-Edmonds, Investment Director at Calculus Capital, commented on the significance of Resurrect Bio’s gene-editing platform, emphasizing its capacity to restore native disease-resistance genes in crops. This innovative approach not only reduces reliance on chemicals but also enhances yields, presenting a promising solution to the pervasive challenge of crop diseases in global agriculture.

Resurrect Bio is now poised to engage seed companies and breeders through additional joint development agreements, aiming to expedite the integration of durable disease-resistance traits into commercial pipelines more efficiently than conventional breeding methods. In a recent development, the company announced its collaboration with Corteva Agriscience in March 2026 to enhance disease resistance in corn.